NCT03148548|Completed
Substudy - Evaluation of Patients With Iliac Vein Thrombosis
Iliofemoral Thrombosis and Postthrombotic Syndrome: Registration and Analysis Within the Frankfurt Thrombophilia Registry
Loading search results
Iliofemoral Thrombosis and Postthrombotic Syndrome: Registration and Analysis Within the Frankfurt Thrombophilia Registry
Sponsor study identifier
observational
85
1 country
1
Study Start
November 2016
Actual (reported)Primary Completion
January 2018
Actual (reported)Study Completion
January 2018
Actual (reported)Patients with previous diagnosis of iliac vein thrombosis are enrolled in this registry. Using standardized questionnaire, clinical data detailing venous thromboembolism and contributing VTE risk factors are recorded. Results of technical and laboratory investigations including screening of thrombophilic disorders were additionally entered into the database.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2016
Actual (reported)March 7, 2017
Actual (reported)May 11, 2017
Actual (reported)January 2018
Actual (reported)January 2018
Actual (reported)Incidence and severity of postthrombotic Syndrome after iliofemoral thrombosis
The incidence and severity of postthrombotic Syndrome will be measured by te VILALLTA-Score
up to 20 years after occurrence of iliofemoral thrombosis
Distribution of gender in Iliofemoral thrombosis
since 1996
Distribution of affected side in Iliofemoral thrombosis
since 1996
Disease-specific quality of life instrument for use in venous diseases of the leg (VEINES-QOL)
1 year
Incidence of venous claudication
1 year
subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
genetic Evaluation of Factor-V-Leiden, Factor-II\_G20210A Mutation;
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Subjects with previous iliofermoral thrombosis, which has been proven by objective measurements (Duplex sonography, phlebography, CT/MRT)
Cardioangiologisches Centrum Bethanien
Frankfurt am Main, Hesse, 60389, Germany
whole blodd, serum
Edelgard Lindhoff-Last, Prof.
Cardioangiologisches Centrum Bethanien
85 participants (actual enrollment reported by the registry).
First Submitted
March 7, 2017
First Posted
May 11, 2017
Study Start
November 2016
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
January 2018
Actual (reported)Study Completion
January 2018
Actual (reported)Last Updated
October 28, 2019
Record last verified: 2019-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: